Policy | July 26, 2022
Funds for R&D in drug discovery and manufacturing :PIB
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
WuXi STA opens a new large scale continuous manufacturing plant
India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Upgrades and global expansion provide additional control, visibility, reliability and recovery for patient-critical, time-and temperature-sensitive products
To strengthen the integrated human-centric preventive health screening ‘Phygital’ ecosystem in India
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
MedTel aims to raise series A for rapid business expansion, product improvement & conducting relevant clinical validation studies.
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Subscribe To Our Newsletter & Stay Updated
